johnson & johnson news

Johnson & Johnson Dips On Q4 Earnings

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Seeking Alpha · 1d

Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.

AOL · 1d

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh

Ben Johnson introduced

USA Today · 1d

Ben Johnson introduced as Bears head coach: 'I wanted to stay in this division'

Ben Johnson expressed gratitude for his time with the Detroit Lions head coach, calling Dan Campbell a "friend" and "mentor" as he takes over Bears

NBC Sports on MSN · 1d

Ben Johnson takes dig at Packers coach Matt LaFleur

Ben Johnson had his choice of several jobs. He chose the Bears. Not only do they have a quarterback to build around, but Johnson also noted they are in a division with which he is familiar. Johnson spent six seasons in the NFC North as an assistant under Dan Campbell.

FOXSports on MSN · 11h

Bears coach Ben Johnson says his offense won't 'look the same as it did in Detroit'

New Bears HC Ben Johnson joined FS1's "Breakfast Ball" and "The Herd" to share what he might do to unlock Caleb Williams' potential.

19h

Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

1don MSN

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Johnson & Johnson price target lowered to $165 from $170 at Raymond James

Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares.

WTTW13h

Johnson Brushes Off Threat of Arrest for Failing to Help Trump’s Mass Deportation Effort

We are not going to be intimidated by those acts of terror to radically shift our way of living,” Mayor Brandon Johnson said.

MassDevice2d

Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

2don MSN

Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness

Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results